Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5294872 | 0.88 | AKR1C3 (0.41) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL11760933 | 0.80 | AKR1C4 (0.67) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL28272928 | 0.80 | ALDH1A1 (0.39) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL11732848 | 0.80 | TTR (0.35) | ALDH1A1ALOX15 | |
| SCHEMBL28166753 | 0.80 | AKR1C4 (0.45) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL588391 | 0.79 | AKR1C3 (0.65) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL11813056 | 0.79 | EIF2AK2 (0.39) | AKR1C3AKR1C2AKR1C1AKR1C4TDP1 | |
| SCHEMBL24665431 | 0.78 | AKR1C3 (0.44) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL11624384 | 0.78 | AKR1C4 (0.44) | AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10 | |
| SCHEMBL8429190 | 0.78 | MYC (0.42) | ALDH1A1MEN1MAPTMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
| US-4187230-A | Preparation of 5-aroyl-pyrrole compounds | ETHYL CORPORATION (US) | 1980-02-05 | — | — | US | disclosed |
| US-4070368-A | ACYLATION, DECARBOXYLATION | MCNEIL LABORATORIES, INCORPORATED (US) | 1978-01-24 | — | — | US | disclosed |
| US-3959216-A | N-(Halobenzoyl) hexahalo-3,5-methanotetrahydrophthalimides | VELSICOL CHEMICAL CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
| US-3959217-A | N-(halobenzoyl)-4,5-dibromo-3,6-methanohexahydrophthalimides | VELSICOL CHEMICAL CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
| US-3953397-A | N-(halobenzoyl)-3,4-dibromohexahydrophthalimides | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-27 | — | — | US | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
| US-3950307-A | FIREPROOFING POLYMERS | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | AKR1C3 877/4885AKR1C2 632/4885AKR1C1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.